Cross‐company collaboration to leverage analytics for clinical quality and accelerate drug development: The IMPALA industry group

Cross‐company collaboration to leverage analytics for clinical quality and accelerate drug development: The IMPALA industry group

Quality functions from pharmaceutical sponsor companies aim to increase the use of analytics in their oversight of Good Clinical Practices and Pharmacovigilance activities. To leverage and accelerate progress, several companies decided to establish a collaborative model. The goals of this collaborat...

Full description

Bibliographic Details
Main Authors: Timothé Ménard, Kyle Young, Laura Siegel, Jennifer Emerson, Robert Studt, Leslie Sidor, The IMPALA Industry Group
Format: Article
Language:English
Published: Wiley 2021-08-01
Series:CPT: Pharmacometrics & Systems Pharmacology
Online Access:https://doi.org/10.1002/psp4.12677
id doaj-4f25ca3e1e574d46be9aacf06152718e
record_format Article
spelling doaj-4f25ca3e1e574d46be9aacf06152718e2021-08-19T17:43:59ZengWileyCPT: Pharmacometrics & Systems Pharmacology2163-83062021-08-0110879980310.1002/psp4.12677Cross‐company collaboration to leverage analytics for clinical quality and accelerate drug development: The IMPALA industry groupTimothé Ménard0Kyle Young1Laura Siegel2Jennifer Emerson3Robert Studt4Leslie Sidor5The IMPALA Industry GroupF. Hoffmann‐La Roche AG Basel SwitzerlandMerck & Co Kenilworth New Jersey USAGlaxoSmithKline (GSK) Collegeville Pennsylvania USABoehringer Ingelheim Pharma GmbH & Co KG Biberach an der Riss GermanyJohnson & Johnson Spring House Pennsylvania USABiogen Cambridge Massachusetts USAQuality functions from pharmaceutical sponsor companies aim to increase the use of analytics in their oversight of Good Clinical Practices and Pharmacovigilance activities. To leverage and accelerate progress, several companies decided to establish a collaborative model. The goals of this collaboration span the sharing of knowledge and ideas, the sharing of analytics methods, discussion of talent upskilling and technology adoption strategies, and collaborative discussion on these potential changes with global Health Authorities.https://doi.org/10.1002/psp4.12677
collection DOAJ
language English
format Article
sources DOAJ
author Timothé Ménard
Kyle Young
Laura Siegel
Jennifer Emerson
Robert Studt
Leslie Sidor
The IMPALA Industry Group
spellingShingle Timothé Ménard
Kyle Young
Laura Siegel
Jennifer Emerson
Robert Studt
Leslie Sidor
The IMPALA Industry Group
Cross‐company collaboration to leverage analytics for clinical quality and accelerate drug development: The IMPALA industry group
CPT: Pharmacometrics & Systems Pharmacology
author_facet Timothé Ménard
Kyle Young
Laura Siegel
Jennifer Emerson
Robert Studt
Leslie Sidor
The IMPALA Industry Group
author_sort Timothé Ménard
title Cross‐company collaboration to leverage analytics for clinical quality and accelerate drug development: The IMPALA industry group
title_short Cross‐company collaboration to leverage analytics for clinical quality and accelerate drug development: The IMPALA industry group
title_full Cross‐company collaboration to leverage analytics for clinical quality and accelerate drug development: The IMPALA industry group
title_fullStr Cross‐company collaboration to leverage analytics for clinical quality and accelerate drug development: The IMPALA industry group
title_full_unstemmed Cross‐company collaboration to leverage analytics for clinical quality and accelerate drug development: The IMPALA industry group
title_sort cross‐company collaboration to leverage analytics for clinical quality and accelerate drug development: the impala industry group
publisher Wiley
series CPT: Pharmacometrics & Systems Pharmacology
issn 2163-8306
publishDate 2021-08-01
description Quality functions from pharmaceutical sponsor companies aim to increase the use of analytics in their oversight of Good Clinical Practices and Pharmacovigilance activities. To leverage and accelerate progress, several companies decided to establish a collaborative model. The goals of this collaboration span the sharing of knowledge and ideas, the sharing of analytics methods, discussion of talent upskilling and technology adoption strategies, and collaborative discussion on these potential changes with global Health Authorities.
url https://doi.org/10.1002/psp4.12677
work_keys_str_mv AT timothemenard crosscompanycollaborationtoleverageanalyticsforclinicalqualityandacceleratedrugdevelopmenttheimpalaindustrygroup
AT kyleyoung crosscompanycollaborationtoleverageanalyticsforclinicalqualityandacceleratedrugdevelopmenttheimpalaindustrygroup
AT laurasiegel crosscompanycollaborationtoleverageanalyticsforclinicalqualityandacceleratedrugdevelopmenttheimpalaindustrygroup
AT jenniferemerson crosscompanycollaborationtoleverageanalyticsforclinicalqualityandacceleratedrugdevelopmenttheimpalaindustrygroup
AT robertstudt crosscompanycollaborationtoleverageanalyticsforclinicalqualityandacceleratedrugdevelopmenttheimpalaindustrygroup
AT lesliesidor crosscompanycollaborationtoleverageanalyticsforclinicalqualityandacceleratedrugdevelopmenttheimpalaindustrygroup
AT theimpalaindustrygroup crosscompanycollaborationtoleverageanalyticsforclinicalqualityandacceleratedrugdevelopmenttheimpalaindustrygroup
_version_ 1721201971295158272

Similar Items